We have reviewed several of these platforms, including Fella Health , IVIM Health , and others
What stood out: CagriSema achieved 23.0% weight loss at 84 weeks (efficacy estimand) Tirzepatide achieved 25.5% On the treatment-regimen estimand, weight loss was 20.2% vs 23.6% Primary endpoint not met: CagriSema did not demonstrate non-inferiority vs tirzepatide on weight loss at 84 weeks Why this matters This is a reminder that in obesity pharmacotherapy, very effective and best-in-class are not the same conversation
doi: 10.1007/s00210-025-04403-5
placebo in the fall of eGFR was better among patients with macroalbuminuria or in those with eGFR between 3060 ml/min/1.73 m2,100 and in the AWARD-7 trial the effect of dulaglutide on renal clinical outcomes and eGFR decline was more pronounced in participants with macroalbuminuria at baseline.66 Likewise, in a post hoc analysis of the LEADER study those patients who experienced a 30% reduction in albuminuria during follow-up had fewer cardiovascular and renal events,101 which confirms that a reduction in albuminuria is associated with a reduction in cardiovascular and renal events.99,102 Finally, the renal benefits of arGLP-1 appear to be additive to those of iSGLT2, which is of particular interest in patients with DKD.85,86,103 Cardiovascular and renal benefits of these drugs have been also demonstrated in real-life studies.104105 The causes of renal protection by some arGLP-1 s are unclear

Long-Acting Insulin (e.g., detemir, glargine U-100) Provides a steady release for 2024 hours with no pronounced peak, supporting basal blood sugar control